Catalog No.:AA0001WJ

1004316-88-4 | 1,3-thiazol-5-ylmethyl N-[(2R,5R)-5-[(2S)-2-{[methyl({[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl})carbamoyl]amino}-4-(morpholin-4-yl)butanamido]-1,6-diphenylhexan-2-yl]carbamate

Name: Name:1,3-thiazol-5-ylmethyl N-[(2R,5R)-5-[(2S)-2-{[methyl({[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl})carbamoyl]amino}-4-(morpholin-4-yl)butanamido]-1,6-diphenylhexan-2-yl]carbamate
Brand: AABLOCKS
SKU: AA0001WJ
Availability: InStock
Rating: 90 (10 reviews)

Pack Size

Purity

Availability

Price(USD)

Quantity

1mg

≥98%

in stock

$53.00 $37.00

- +

5mg

98%

in stock

$132.00 $93.00

- +

25mg

98%

in stock

$339.00 $237.00

- +

100mg

98%

in stock

$902.00 $632.00

- +

Technical Information
Properties
Downstream Synthesis Route
Literature
Request for Quotation
Download SDS

Technical Information
Properties
Downstream Synthesis Route
Literature

Technical Information

Catalog Number:

AA0001WJ

Chemical Name:

1,3-thiazol-5-ylmethyl N-[(2R,5R)-5-[(2S)-2-{[methyl({[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl})carbamoyl]amino}-4-(morpholin-4-yl)butanamido]-1,6-diphenylhexan-2-yl]carbamate

CAS Number:

1004316-88-4

Molecular Formula:

C40H53N7O5S2

Molecular Weight:

776.0227

MDL Number:

MFCD18251449

SMILES:

O=C(N[C@@H](Cc1ccccc1)CC[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)N(Cc1csc(n1)C(C)C)C)CCN1CCOCC1)OCc1cncs1

Properties

Computed Properties

Complexity:

1120

Covalently-Bonded Unit Count:

Defined Atom Stereocenter Count:

Heavy Atom Count:

Hydrogen Bond Acceptor Count:

Hydrogen Bond Donor Count:

Rotatable Bond Count:

XLogP3:

5.7

Downstream Synthesis Route

1247119-33-0

CASUnavailable

1004316-88-4

[1]CurrentPatentAssignee:GILEADSCIENCESINC-US2010/256366,2010,A1Locationinpatent:Page/Pagecolumn22-23

CASUnavailable

1004316-88-4

1407483-45-7

[1]CurrentPatentAssignee:GILEADSCIENCESINC-WO2012/151165,2012,A1Locationinpatent:Page/Pagecolumn22

1004316-88-4

97-67-6

1407483-49-1

[1]CurrentPatentAssignee:GILEADSCIENCESINC-WO2012/151165,2012,A1Locationinpatent:Page/Pagecolumn27

1004316-88-4

87-69-4

1453350-81-6

[1]CurrentPatentAssignee:GILEADSCIENCESINC-WO2012/151165,2012,A1Locationinpatent:Page/Pagecolumn19

1004316-88-4

144-62-7

1453350-69-0

[1]CurrentPatentAssignee:GILEADSCIENCESINC-WO2012/151165,2012,A1Locationinpatent:Page/Pagecolumn20

Literature

Title: Pharmacokinetic enhancers in HIV therapeutics.

Journal: Clinical pharmacokinetics 20141001

Title: Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro.

Journal: Antimicrobial agents and chemotherapy 20121001

Title: Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function.

Journal: Journal of acquired immune deficiency syndromes (1999) 20120901

Title: Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.

Journal: Expert opinion on pharmacotherapy 20120901

Title: [A single tablet against HIV: new combination preparation improves therapy].

Journal: Deutsche medizinische Wochenschrift (1946) 20120801

Title: Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.

Journal: Lancet (London, England) 20120630

Title: Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.

Journal: Lancet (London, England) 20120630

Title: Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection.

Journal: AIDS (London, England) 20110924

Title: Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.

Journal: AIDS (London, England) 20110327

Title: Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.

Journal: Journal of acquired immune deficiency syndromes (1999) 20101101

Title: Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer.

Journal: ACS medicinal chemistry letters 20100812

Title: Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity.

Journal: Clinical pharmacology and therapeutics 20100301

Title: Lianhong Xu, et al. Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer. ACS Med. Chem. Lett., 2010, 1 (5), pp 209–213

Title: Temesgen Z. Cobicistat, a pharmacoenhancer for HIV treatments. Drugs Today (Barc). 2013 Apr;49(4):233-7.

Quotation Request

Company Name:

Contact Person:

Email:

Quantity Required:

Country:

Additional Info:

SDS